<DOC>
	<DOCNO>NCT01330797</DOCNO>
	<brief_summary>Purpose To evaluate cataractogenic effect intravitreal ranibizumab use Lens Opacity Classification System III ( LOCS III ) . Settings Cases diagnosis wet AMD include university practice base prospective study . Methods All case monthly injection intravitreal ranibizumab first 3 month ; subsequently OCT-guided pro nata injection regimen adopt . All case comprehensive eye examination LOCS III evaluation baseline 1 , 3 , 6 12 month initial injection . Examination outcomes change baseline LOCS III grade 12 month record . Results Eighteen eye 13 case ( 7 female , 6 male ) include study . The mean age baseline 75,3 + 6,6 year . A mean 3,4 + 0,7 injection give eye . Mean follow-up 13,83 + 2,33 month . Baseline mean visual acuity improve 1,04 + 0,10 logMAR unit 0,76 + 0,26 logMAR unit 3 injection ( P &lt; 0.05 ) . At 12th month follow-up mean visual acuity 0,71 + 0,27 logMAR unit . According LOCS III grade none case prominent change nuclear color , nuclear opalescence , cortical posterior subcapsular opacification throughout follow-up . IOP remain stable follow-up point . No complication record throughout study . Conclusion Intravitreal ranibizumab efficient treatment wet AMD . Results LOCS III assessment pilot study suggest intravitreal ranibizumab effect progression lens opacity .</brief_summary>
	<brief_title>The Effect Ranibizumab Eye Lens Opacity Cases With Age-Related Macular Degeneration</brief_title>
	<detailed_description>In last decade , significant progress make treatment wet AMD . At present intravitreal anti-VEGF therapy become mainstay treatment . Nevertheless , intravitreal application hazardous procedure wide range complication . Endophthalmitis , intraocular pressure ( IOP ) elevation , retinal detachment , vitreous hemorrhage , cataract among major complication . The current study focus cataractogenic potential intravitreal ranibizumab . Cataract formation follow intravitreal application frequently associate inadvertent trauma procedure . However , occasionally drug -itself- may precipitate cataract formation . Accelerated formation cataract , previously show possible cause decrease visual acuity , case receive intravitreal injection triamcinolone . However , prospective study , yet , assess anti-VEGF agent relate cataract progression case AMD . Herein , investigator investigate cataractogenic effect intravitreal ranibizumab use Lens Opacity Classification System III ( LOCS III ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Neovascular agerelated macular degeneration case undergo ranibizumab treatment Phakic patient History previous injection triamcinolone antiVEGF drug Individuals undergone cataract extraction Cases intraocular surgery within last 3 month Cases laser treatment within 1 month ( include YAG laser iridotomy ) Cases use systemic steroid antiglaucomatous drop</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Cataract</keyword>
	<keyword>Intravitreal</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>LOCS III</keyword>
</DOC>